| abstract |
Compound of formula (I) n n n wherein: n R 1 is hydrogen or C 1 -C 6 -alkyl optionally substituted by C 3 -C 6 -cycloylalkyl; n R 2 and R 3 together with the nitrogen form a saturated or unsaturated 5- or 6-membered heterocyclic ring optionally containing nitrogen or oxygen as an additional heteroatom, wherein the heterocyclic ring thereof is substituted by a group selected from phenyl, benzyl, and diphenylmethyl, each optionally mono- or di-substituted by one or two groups selected from CF 3 , C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, phenyl, benzyl, halogen, and OH, or n R 2 and R 3 together with the nitrogen form a saturated or unsaturated 5- or 6-membered heterocyclic ring optionally containing nitrogen or oxygen as an additional heteroatom, the heterocyclic ring thereof linked via a single bond, a methylene-bridge, or spiro-connected to another saturated or unsaturated heterocyclic group containing one or two heteroatoms selected from oxygen and nitrogen, the heterocyclic group being optionally mono- or di-substituted by a group selected from CF 3 , C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, phenyl, benzyl, halogen, =O, and OH, or n R 2 and R 3 together with the nitrogen form a saturated or unsaturated bi- or tricyclic heterocyclic ring system optionally containing nitrogen or oxygen as an additional heteroatom, the heterocyclic ring system is optionally substituted by a group selected from CF 3 , C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, phenyl, benzyl, halogen, =O, and OH; and n A is C 2 -C 6 -alkenylene, n their pharmaceutically acceptable salts, their preparation, and their use for therapeutic purposes. |